伊立替康联合洛铂对依托泊苷方案化疗失败小细胞肺癌肝转移患者的疗效及安全性评价

目的：评价伊立替康联合洛铂方案治疗依托泊苷方案化疗失败后的小细胞肺癌肝转移患者的疗效和安全性。方法回顾性分析2015年1月至2016年1月接受伊立替康联合洛铂方案治疗的9例依托泊苷方案化疗失败后的肺小细胞癌肝转移患者的临床资料，观察该方案的疗效和安全性。结果9例患者经过化疗后，所有患者肝功能均得到改善。完全缓解0例，部分缓解3例，稳定6例，有效率33耨．3％（3／9），9例患者中位生存期12．0个月。毒副反应主要为血液学毒性，其中Ⅲ～Ⅳ度白细胞、中性粒细胞及血小板减少发生率分别为11．1％、11．1％、0。结论伊立替康联合洛铂方案治疗依托泊苷方案化疗失败后的小细胞肺癌肝转移患者疗效确切，耐受性好，值得进一步临床研究。

Therapeutic effects and safety of irinotecan combined with lobaplatin on small cell lung cancer with hepatic metastasis after failure to etoposide chemotherapy scheme

Objective To evaluate the therapeutic effects and safety of irinotecan (CP-11) combined with lobaplatin on small cell lung cancer with hepatic metastasis after failure to etoposide chemotherapy scheme.Methods The clinical data anout 9 patients with small cell lung cancer complicated by hepatic metastasis,who were treated by irinotecan combined with lobaplatin in our hospital from January 2015 to January 2016 after failure to etoposide chemotherapy scheme, were retrospectively analyzed,and the therapeutic effects and safety of the combination treatment scheme were evaluated.Results The liver function of the 9 patients was improved after chemotherapy in whom there was no complete remission case,however, there were 3 cases of partial remission and 6 cases of stable state of disease, with the effective rate being 33.3%(3/9).In the 9 patients,the median survival duration was 12.0 months.The toxic and adverse reactions of patients were mainly hematological toxicity in which the incidence rates of leukocyte decrease at grade Ⅲ or Ⅳ, the neutropenia and thrombocytopenia were 11.1%,11.1%, 0, respectively.Conclusion The irinotecan combined with lobaplatin is effective and well tolerable in treating small cell lung cancer with hepatic metastasis after failure to etoposide based chemotherapy, thus, which is worth researching further.